Two breast cancer drugs could get a boost from new expert advice. The U.S. Preventive Services Task Force now recommends that doctors offer the drugs--tamoxifen and raloxifene, a.k.a. Eli Lilly's ($LLY) Evista--to high-risk patients to prevent the disease.
Pfizer won coveted "breakthrough" status from the FDA for its experimental breast cancer drug palbociclib after impressive interim results from a mid-stage study.
The U.K.'s cost-effectiveness watchdog has turned away Afinitor for breast cancer. The Novartis drug doesn't offer enough value for the money, the National Institute for Health and Clinical Excellence says.
Genentech, the venerable biotech unit of Roche, has been cranking out new mobile apps to stay ahead in the biopharma world.
The FDA gave approval to T-DM1, which will be marketed as Kadcyla, for patients with HER2-positive, late-stage (metastatic) breast cancer.
The first court fight over the old miscarriage drug DES and alleged links to breast cancer didn't last long. On the second day of the trial, Eli Lilly ($LLY) settled with the four plaintiffs, who had claimed that the drug, used by their mother during pregnancy, caused them to develop the disease.
Fifty to 80 years ago, the synthetic estrogen DES was commonly prescribed to women who were at risk for miscarriage and premature births. Now dozens of their daughters who have developed breast cancer are suing drugmakers.
Avastin has struck out at NICE again. The U.K. cost-effectiveness watchdog says it's not inclined to back the blockbuster Roche ($RHHBY) drug as a treatment for ovarian cancer. At about $4,000 per month, NICE said, Avastin simply doesn't deliver enough value for the money.
Strong Phase II data for Pfizer's dual-kinase blocker for breast cancer has analysts anticipating a "mega-blockbuster."
They're popping corks at Celgene ($CELG) headquarters. The company's cancer drug Abraxane aced a study in pancreatic cancer, boosting patients' survival and forming the foundation for a new FDA approval app.